| Xencor, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120128663 | Fc VARIANTS THAT EXTEND ANTIBODY HALF-LIFE - The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody. | 05-24-2012 |
| 20120088905 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index. | 04-12-2012 |
| 20120028304 | ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS - The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo. | 02-02-2012 |
| 20120014950 | Antibodies That Specifically Bind to DR3 - The present invention relates to antibodies, antibody fragments, and related molecules that specifically bind to DR3 receptors. Such antibodies have uses, for example, in the prevention, detection, diagnosis, treatment or amelioration of a disease or disorder, especially inflammatory and autoimmune diseases and other immune system disorders, such as Crohn's disease, colitis, Inflammatory Bowel Disease, arthritis, asthma, Multiple Sclerosis, atherosclerosis, and allergic disorders. The invention also relates to nucleic acid molecules encoding anti-DR3 receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially inflammatory or autoimmune disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to DR3 receptor. | 01-19-2012 |
| 20120014943 | Optimized Anti-CD30 Antibodies - An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody. | 01-19-2012 |
| 20110287032 | NOVEL CTLA4-IG IMMUNOADHESINS - The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes. | 11-24-2011 |
| 20110250681 | Fc Variants with Optimized Properties - The present invention relates to Fc variants with optimized properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized properties, and methods for using Fc variants with optimized properties. | 10-13-2011 |
| 20110236969 | METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING CONTENT AND COMPOSITIONS THEREOF - The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods. | 09-29-2011 |
| 20110236375 | ANTIBODY VARIANTS WITH ENHANCED COMPLEMENT ACTIVITY - The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes. | 09-29-2011 |
| 20110189178 | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions - The present application relates to therapeutic moieties displaying reduced immunogen response, particularly for therapeutic purposes. | 08-04-2011 |
| 20110110928 | FC VARIANTS WITH ALTERED BINDING TO FCRN - The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index. | 05-12-2011 |
| 20110064727 | Immunoglobulin Variants Outside the Fc Region - The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application. | 03-17-2011 |
| 20110054151 | COMPOSITIONS AND METHODS FOR SIMULTANEOUS BIVALENT AND MONOVALENT CO-ENGAGEMENT OF ANTIGENS - Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions. | 03-03-2011 |
| 20110027276 | Optimized CD40 Antibodies and Methods of Using the Same - The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention. | 02-03-2011 |
| 20110021755 | Optimized Fc Variants - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 01-27-2011 |
| 20100317834 | IgG Immunoglobulin Variants with Optimized Effector Function - The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes. | 12-16-2010 |
| 20100311954 | Optimized Proteins that Target Ep-CAM - Humanized Ep-CAM-targeting antibodies and methods of making and using the same are provided. | 12-09-2010 |
| 20100190247 | Methods of Generating Variant Proteins with Increased Host String Content - The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods. | 07-29-2010 |
| 20100104557 | Optimized Antibodies that Target HM1.24 - The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed. | 04-29-2010 |
| 20100080814 | NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS - The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma. | 04-01-2010 |
| 20100004431 | HUMAN EQUIVALENT MONOCLONAL ANTIBODIES ENGINEERED FROM NONHUMAN VARIABLE REGIONS - The present invention is directed to the creation of human equivalent CDRs and antibodies containing them by a method of producing an antibody which specifically binds to an antigen. | 01-07-2010 |
| 20090215991 | Optimized Fc Variants and methods for their generation - The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 08-27-2009 |
| 20090214526 | Optimized Fc Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 08-27-2009 |
| 20090142340 | Optimized Fc Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 06-04-2009 |
| 20090136485 | Methods and compositions for inhibiting CD32B expressing cells - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. | 05-28-2009 |
| 20090092599 | Optimized Fc variants and methods for their generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 04-09-2009 |
| 20090081208 | Optimized Fc variants and methods for their generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 03-26-2009 |
| 20090068177 | Optimized Fc variants and methods for their generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 03-12-2009 |
| 20090068175 | Optimized FC Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 03-12-2009 |
| 20090053240 | Novel Immunoglobulin Insertions, Deletions and Substitutions - An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide. | 02-26-2009 |
| 20090053211 | Optimized Fc variants - The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 02-26-2009 |
| 20090042291 | Optimized Fc variants - The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 02-12-2009 |
| 20090010920 | Fc Variants Having Decreased Affinity for FcyRIIb - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 01-08-2009 |
| 20080292621 | Optimized Fc Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 11-27-2008 |
| 20080248028 | Immunoglobulin Variants Outside the Fc Region - The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application. | 10-09-2008 |
| 20080242845 | Fc variants with optimized properties - The present invention relates to Fc variants with optimized properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized properties, and methods for using Fc variants with optimized properties. | 10-02-2008 |
| 20080206242 | METHOD OF TREATMENT OF TH2-MEDIATED CONDITIONS USING OPTIMIZED ANTI-CD30 ANTIBODIES - A method of treating Th2-mediated conditions, e.g., atopic conditions, e.g., atopic asthma and/or atopic dermatitis, using effective amount of an antibody that targets CD30, where the antibody has at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. | 08-28-2008 |
